{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=NR3C1&page=2",
    "query": {
      "condition": "NR3C1",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=NR3C1&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T16:26:39.149Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02788981",
      "title": "Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Mifepristone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Nab-Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2017-03-28",
      "completion_date": "2026-08",
      "has_results": true,
      "last_update_posted_date": "2025-06-10",
      "last_synced_at": "2026-07-22T16:26:39.149Z",
      "location_count": 5,
      "location_summary": "Birmingham, Alabama • Chicago, Illinois • Evanston, Illinois + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02788981"
    },
    {
      "nct_id": "NCT03622112",
      "title": "A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "AZD7594 DPI 55μg/50μg.",
          "type": "DRUG"
        },
        {
          "name": "AZD7594 DPI 99 µg/90 µg",
          "type": "DRUG"
        },
        {
          "name": "AZD7594 DPI 198 µg/180 µg",
          "type": "DRUG"
        },
        {
          "name": "AZD7594 DPI 396 µg/360 µg once daily.",
          "type": "DRUG"
        },
        {
          "name": "AZD7594 DPI 792 µg/720 µg",
          "type": "DRUG"
        },
        {
          "name": "Placebo for AZD7594 once daily.",
          "type": "DRUG"
        },
        {
          "name": "FF 100 µg once daily (open-label)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 808,
      "start_date": "2019-01-02",
      "completion_date": "2019-09-30",
      "has_results": true,
      "last_update_posted_date": "2020-11-27",
      "last_synced_at": "2026-07-22T16:26:39.149Z",
      "location_count": 21,
      "location_summary": "Sheffield, Alabama • Phoenix, Arizona • Fullerton, California + 18 more",
      "locations": [
        {
          "city": "Sheffield",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Gold River",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03622112"
    },
    {
      "nct_id": "NCT04329949",
      "title": "Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Pancreatic Ductal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Relacorilant, 100 mg and 25 mg",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Corcept Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2020-06-30",
      "completion_date": "2022-03-25",
      "has_results": true,
      "last_update_posted_date": "2023-11-18",
      "last_synced_at": "2026-07-22T16:26:39.149Z",
      "location_count": 18,
      "location_summary": "Scottsdale, Arizona • Duarte, California • Los Angeles, California + 14 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04329949"
    },
    {
      "nct_id": "NCT02645253",
      "title": "A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Asthma",
        "Chronic Obstructive Pulmonary Disease COPD"
      ],
      "interventions": [
        {
          "name": "AZD7594 inhalation powder (200 μg)",
          "type": "DRUG"
        },
        {
          "name": "AZD7594 inhalation powder (400 μg)",
          "type": "DRUG"
        },
        {
          "name": "AZD7594 pressurized inhalation suspension (200 μg)",
          "type": "DRUG"
        },
        {
          "name": "AZD7594 placebo inhalation powder",
          "type": "DRUG"
        },
        {
          "name": "AZD7594 placebo pressurized inhalation suspension",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "45 Years",
        "sex": "MALE",
        "summary": "20 Years to 45 Years · Male only"
      },
      "enrollment_count": 27,
      "start_date": "2016-01-12",
      "completion_date": "2016-04-17",
      "has_results": true,
      "last_update_posted_date": "2018-02-19",
      "last_synced_at": "2026-07-22T16:26:39.149Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02645253"
    },
    {
      "nct_id": "NCT00039715",
      "title": "Effects of Hydrocortisone in Patients With Post-Traumatic Stress Disorder",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Post-Traumatic Stress Disorders",
        "Healthy"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Mental Health (NIMH)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 93,
      "start_date": "2002-06",
      "completion_date": "2004-09",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-07-22T16:26:39.149Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00039715"
    },
    {
      "nct_id": "NCT03324555",
      "title": "Study of ORIC-101 in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "ORIC-101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ORIC Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2017-10-19",
      "completion_date": "2017-12-18",
      "has_results": false,
      "last_update_posted_date": "2018-04-05",
      "last_synced_at": "2026-07-22T16:26:39.149Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03324555"
    },
    {
      "nct_id": "NCT02185872",
      "title": "CrossFit Exercise to Improve Glucose Control for Overweight and Obese Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hyperglycemia"
      ],
      "interventions": [
        {
          "name": "High-Intensity Functional Training",
          "type": "OTHER"
        },
        {
          "name": "Aerobic and Resistance Training",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Kansas State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 23,
      "start_date": "2012-02",
      "completion_date": "2012-05",
      "has_results": false,
      "last_update_posted_date": "2015-03-31",
      "last_synced_at": "2026-07-22T16:26:39.149Z",
      "location_count": 1,
      "location_summary": "Manhattan, Kansas",
      "locations": [
        {
          "city": "Manhattan",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02185872"
    },
    {
      "nct_id": "NCT04452500",
      "title": "Phase IIa Trial of a Selective Glucocorticoid Receptor Antagonist in the Treatment of Veterans With Posttraumatic Stress Disorder (PTSD) (Seven Study)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "PTSD"
      ],
      "interventions": [
        {
          "name": "CORT108297",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "18 Years to 69 Years"
      },
      "enrollment_count": 40,
      "start_date": "2022-10-15",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-29",
      "last_synced_at": "2026-07-22T16:26:39.149Z",
      "location_count": 2,
      "location_summary": "Tuscaloosa, Alabama • San Francisco, California",
      "locations": [
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04452500"
    },
    {
      "nct_id": "NCT04308590",
      "title": "A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypercortisolism"
      ],
      "interventions": [
        {
          "name": "Relacorilant",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Corcept Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 137,
      "start_date": "2020-07-27",
      "completion_date": "2024-09-19",
      "has_results": true,
      "last_update_posted_date": "2025-09-04",
      "last_synced_at": "2026-07-22T16:26:39.149Z",
      "location_count": 22,
      "location_summary": "Birmingham, Alabama • Stanford, California • Torrance, California + 19 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04308590"
    },
    {
      "nct_id": "NCT04373265",
      "title": "Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adrenocortical Carcinoma"
      ],
      "interventions": [
        {
          "name": "Relacorilant",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Corcept Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2020-09-30",
      "completion_date": "2024-01-12",
      "has_results": false,
      "last_update_posted_date": "2024-02-23",
      "last_synced_at": "2026-07-22T16:26:39.149Z",
      "location_count": 6,
      "location_summary": "Stanford, California • Tampa, Florida • Ann Arbor, Michigan + 3 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04373265"
    }
  ]
}